{"doi":"10.2217/cer-2019-0061","title":"Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma","abstract":"<jats:p>\n            <jats:bold>Aim</jats:bold>\n            To conduct a systematic literature review of high-risk resectable cutaneous melanoma adjuvant therapeutics and compare safety and efficacy.\n            <jats:bold>Methods:</jats:bold>\n            The systematic literature review included randomized controlled trials investigating: dabrafenib plus trametinib (DAB + TRAM), nivolumab, pembrolizumab, ipilimumab, vemurafenib, chemotherapy and interferons. Outcomes included overall survival (OS), relapse-free survival, distant metastasis-free survival and safety. All outcomes were synthesized using Bayesian network meta-analysis.\n            <jats:bold>Results:</jats:bold>\n            Across relapse-free survival, distant metastasis-free survival and OS, DAB + TRAM had the lowest estimated hazards of respective events relative to all other treatments (exception relative to nivolumab in OS). Differences were significant relative to placebo, chemotherapy, interferons and ipilimumab.\n            <jats:bold>Conclusion:</jats:bold>\n            DAB + TRAM has improved efficacy over historical treatment options (ipilimumab, interferons and chemotherapy) and comparable efficacy with other targeted and immune checkpoint inhibitors.\n          </jats:p>","journal":"Journal of Comparative Effectiveness Research","year":2019,"id":637014,"datarank":0.3958585994422889,"base_score":2.639057329615259,"endowment":2.639057329615259,"self_citation_contribution":0.3958585994422889,"citation_network_contribution":0.0,"self_endowment_contribution":0.3958585994422889,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1653740,"name":"Roy Koruth","orcid":null,"position":1,"is_corresponding":false},{"id":30237,"name":"Steve Kanters","orcid":"0000-0003-0322-5398","position":2,"is_corresponding":false},{"id":56813,"name":"Eric Druyts","orcid":null,"position":3,"is_corresponding":false},{"id":1561921,"name":"Ahmad Tarhini","orcid":null,"position":4,"is_corresponding":false},{"id":639050,"name":"Rohini Sharma","orcid":"0000-0003-2441-549X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma","abstract":"<jats:p>\n            <jats:bold>Aim</jats:bold>\n            To conduct a systematic literature review of high-risk resectable cutaneous melanoma adjuvant therapeutics and compare safety and efficacy.\n            <jats:bold>Methods:</jats:bold>\n            The systematic literature review included randomized controlled trials investigating: dabrafenib plus trametinib (DAB + TRAM), nivolumab, pembrolizumab, ipilimumab, vemurafenib, chemotherapy and interferons. Outcomes included overall survival (OS), relapse-free survival, distant metastasis-free survival and safety. All outcomes were synthesized using Bayesian network meta-analysis.\n            <jats:bold>Results:</jats:bold>\n            Across relapse-free survival, distant metastasis-free survival and OS, DAB + TRAM had the lowest estimated hazards of respective events relative to all other treatments (exception relative to nivolumab in OS). Differences were significant relative to placebo, chemotherapy, interferons and ipilimumab.\n            <jats:bold>Conclusion:</jats:bold>\n            DAB + TRAM has improved efficacy over historical treatment options (ipilimumab, interferons and chemotherapy) and comparable efficacy with other targeted and immune checkpoint inhibitors.\n          </jats:p>","is_dataset_classified":null,"base_score":2.639057329615259,"endowment":2.639057329615259,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"31778073","pmcid":null,"openalex_id":"https://openalex.org/W2989785091","authors":[],"funders":[],"total_grants":0,"fwci":0.8052,"citation_percentile":0.74545366,"influential_citations":0,"citation_trend":[{"year":2020,"count":1},{"year":2021,"count":5},{"year":2022,"count":3},{"year":2023,"count":2},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://becarispublishing.com/doi/pdf/10.2217/cer-2019-0061","host_type":"publisher"},{"url":"https://doi.org/10.2217/cer-2019-0061","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/31778073","host_type":"repository"}],"fields_of_study":["Cutaneous Melanoma Detection and Management","Melanoma and MAPK Pathways","HER2/EGFR in Cancer Research","Adult","Antibodies, Monoclonal, Humanized","Antineoplastic Agents, Immunological","Antineoplastic Combined Chemotherapy Protocols","Bayes Theorem","Combined Modality Therapy","Disease-Free Survival","Female","Humans","Imidazoles","Interferons","Ipilimumab","Male","Melanoma","Middle Aged","Neoplasm Recurrence, Local","Nivolumab","Oximes","Pyridones","Pyrimidinones","Randomized Controlled Trials as Topic","Skin Neoplasms","Treatment Outcome","Vemurafenib"],"mesh_terms":["Network Meta-Analysis","Antineoplastic Agents, Immunological","Ipilimumab","Vemurafenib","Nivolumab","Adult","Antineoplastic Combined Chemotherapy Protocols","Bayes Theorem","Combined Modality Therapy","Female","Humans","Imidazoles","Interferons","Male","Melanoma","Middle Aged","Neoplasm Recurrence, Local","Oximes","Pyridones","Pyrimidinones","Skin Neoplasms","Randomized Controlled Trials as Topic","Treatment Outcome","Disease-Free Survival","Antibodies, Monoclonal, Humanized"],"keywords":["Medicine","Ipilimumab","Dabrafenib","Trametinib","Nivolumab","Oncology","Internal medicine","Vemurafenib","Pembrolizumab","Melanoma","Immunotherapy","Cancer","Cancer research","Systematic Literature Review","Network Meta-analysis","Adjuvant Melanoma"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T18:09:13.365146Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}